Joined: 2/17/2019
Posts: 379
|
The idea of repurposing montelukast for Alzheimer's disease is buoyed by its excellent safety record. However, the tablet poorly enters the bloodstream, which IntelGenx hopes it can overcome with a thin oral film formulation.
Even though Prof. Abbracchio isn't involved with the IntelGenx program, she contends that there is a strong scientific rationale behind developing montelukast to treat neurodegenerative diseases. She and Prof. Aigner also are discussing further preclinical research with montelukast.
In a research report last month, Ben Haynor, an analyst with Aegis Capital, notes Alzheimer's is a growing problem as the population ages, yet many therapeutic approaches have failed over the past several decades.
|